Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06384222 · ClinicalTrials.gov registry record · Phase 2
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
A Phase 2 study of Prostate Cancer and High Risk Prostate Carcinoma, sponsored by Ivan de Kouchkovsky, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06384222: Recruiting Phase 2 study of Prostate Cancer and High Risk Prostate Carcinoma, sponsored by Ivan de Kouchkovsky, MD.
NCT06384222 is a Phase 2 study of Prostate Cancer and High Risk Prostate Carcinoma that is actively recruiting participants, run by Ivan de Kouchkovsky, MD. The registered enrollment target is 32 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06384222, a Phase 2 study of Prostate Cancer and High Risk Prostate Carcinoma, is actively recruiting participants, sponsored by Ivan de Kouchkovsky, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the use of hyperpolarized 13C MRI (HP 13C MRI) and the HP-derived 13C pyruvate-to-lactate conversion rate constant (kPL) as an early response biomarker in men with treatment-naïve, high-risk, localized or locally advanced prostate cancer receiving neoadjuvant therapy.
Primary Outcome
Mean changes in intratumoral kPL from baseline to 4 weeks will be reported. For participants with \>1 intraprostatic lesions detected on baseline scan, change in kPL will be calculated on using the lesion with the highest initial kPL.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging (MRI)
- DRUG Prednisone
- DRUG Abiraterone acetate
- DRUG Hyperpolarized [1-13C] pyruvate (HP 13C)
- PROCEDURE Non-investigational radical prostatectomy (RP)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-12-09 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
What NCT06384222 shows while recruiting
NCT06384222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT06384222 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06384222 about?
NCT06384222 is a clinical study titled "Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone". This study will evaluate the use of hyperpolarized 13C MRI (HP 13C MRI) and the HP-derived 13C pyruvate-to-lactate conversion rate constant (kPL) as an early response biomarker in men with treatment-naïve, high-risk, localized or locally advanced prostate cancer receiving neoadjuvant therapy.
What is the current status of trial NCT06384222?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2024-12-09. Estimated completion is 2027-09-30.
What conditions does trial NCT06384222 study?
This clinical trial studies the following conditions: Prostate Cancer, High Risk Prostate Carcinoma.
What interventions are being tested in trial NCT06384222?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Prednisone (DRUG), Abiraterone acetate (DRUG), Hyperpolarized [1-13C] pyruvate (HP 13C) (DRUG), Non-investigational radical prostatectomy (RP) (PROCEDURE).
Who is sponsoring clinical trial NCT06384222?
This trial is sponsored by Ivan de Kouchkovsky, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06384222 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06384222's enrollment target sits among peer trials
32 566th of 735 higher than 159 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI